Eurobio-Scientific SA (ALERS) AI Stock Analysis

• Market Cap: €225.12M
• Dividend Yield: N/A
• Average Volume (3M): 968.00
• Price to Earnings (P/E): 27.0
• Beta (1Y): -0.32
• Revenue Growth: 12.47%
• EPS Growth: -65.87%
• Country: FR
• Employees: 329
• Sector: Healthcare
• Sector Strength: 45
• Industry: Medical - Devices
• EPS (TTM): 0.23
• Shares Outstanding: 10,248,871
• 10 Day Avg. Volume: 1,061
• 30 Day Avg. Volume: 968
• PEG Ratio: -6.95
• Price to Book (P/B): 1.45
• Price to Sales (P/S): 1.67
• P/FCF Ratio: 19.24
• Enterprise Value/Market Cap: N/A
• Enterprise Value/Revenue: N/A
• Enterprise Value/Gross Profit: N/A
• Enterprise Value/Ebitda: N/A
• 1Y Price Target: N/A
• Price Target Upside: N/A
• Rating Consensus: N/A
• Number of Analyst Covering: 0
• EPS Forecast (FY): 1.13
• Revenue Forecast (FY): €175.90M

• Rating: 55 Neutral
• Price Target: €26.00 ▲(7.66% Upside)
• Action: Reiterated Date: 10/10/25
• Date: Action: Reiterated 10/10/25

Eurobio-Scientific SA's overall stock score is primarily influenced by its mixed financial performance and weak technical indicators. The high P/E ratio indicates overvaluation, further impacting the score negatively. The absence of earnings call data and corporate events means these factors did not contribute to the score.

Positive Factors

Revenue Growth

Strong revenue growth indicates robust demand for Eurobio-Scientific's diagnostic products, supporting long-term business expansion and market penetration.

Balance Sheet Strength

A strong equity ratio and low debt-to-equity ratio provide financial stability, allowing Eurobio-Scientific to invest in growth opportunities without excessive leverage.

Cash Generation

Effective cash generation relative to net income ensures Eurobio-Scientific can sustain operations and fund future growth initiatives, enhancing long-term viability.

Negative Factors

Profitability Margins

Declining operational efficiency, as indicated by reduced EBIT and EBITDA margins, could hinder Eurobio-Scientific's ability to maintain profitability, impacting long-term financial health.

Operating Cash Flow Decline

A significant decline in operating cash flow may strain liquidity, limiting Eurobio-Scientific's capacity to invest in growth and meet short-term obligations.

Return on Equity

A declining return on equity suggests reduced efficiency in generating profits from shareholders' investments, potentially affecting investor confidence and future capital raising.

Eurobio-Scientific SA Business Overview & Revenue Model

Company Description

Eurobio Scientific Société anonyme designs, develops, and commercializes specialty diagnostic products in the areas of transplantation, infectious diseases, life-science, and cancer. The company offers Tetanus Quick Stick, a test that is used in emergency clinics for the determination of the tetanus vaccination status of a patient; and commercializes cell culture media, molecular biology reagents, and proprietary antibodies. Its in-house development products include the BJI InoPlex, a multiplex serological test used for the diagnosis of prosthetic joint infections; EBX-044 PCR test to enable the identification of SARS-CoV-2 variants; and licensed products comprise AlloMap, a gene-expression profiling based blood test for the surveillance of heart-transplant patients. The company was formerly known as Diaxonhit and changed its name to Eurobio Scientific Société anonyme in June 2018. Eurobio Scientific Société anonyme was incorporated in 1997 and is headquartered in Les Ulis, France.

How the Company Makes Money

Eurobio-Scientific SA generates revenue primarily through the sale of its diagnostic products, including reagents, kits, and associated laboratory equipment. The company has established key revenue streams from both direct sales to healthcare providers and partnerships with distributors and laboratories that enhance its market reach. Additionally, Eurobio-Scientific may benefit from strategic collaborations with research institutions and other biotech companies, which can lead to joint ventures, licensing agreements, and co-development projects that further diversify its income sources. The company also focuses on innovation and the development of new diagnostic technologies, which can create additional revenue opportunities through product launches and expanded market penetration.

Eurobio-Scientific SA Financial Statement Overview

Summary

Eurobio-Scientific SA exhibits a mixed financial performance. The revenue growth is promising, yet profitability margins and cash flow generation are under pressure. The company's strong equity position and low leverage provide stability, but declining ROE and cash flow metrics highlight areas needing improvement.

Income Statement

Eurobio-Scientific SA has demonstrated stable profitability with a Gross Profit Margin of 46.43% and a Net Profit Margin of 2.58% for 2024. The Revenue Growth Rate showed a healthy increase of 18.59% from 2023 to 2024. However, there has been a noticeable decline in EBIT and EBITDA Margins compared to previous years, indicating reduced operational efficiency.

Balance Sheet

The company's balance sheet reflects a strong Equity Ratio of 69.56%, suggesting a solid financial foundation. The Debt-to-Equity Ratio is low at 0.19, indicating conservative leverage. However, the Return on Equity has decreased to 2.24% for 2024, which is a concern for shareholders seeking higher returns.

Cash Flow

Eurobio-Scientific SA's cash flow statement shows a decline in Operating Cash Flow by 37.57% from 2023 to 2024, impacting liquidity. Despite this, the Free Cash Flow to Net Income Ratio remains robust at 3.37, indicating effective cash generation relative to net income. However, the Free Cash Flow Growth Rate is negative, reflecting challenges in maintaining positive free cash flow growth.

Breakdown	TTM	Dec 2024	Dec 2023	Dec 2022	Dec 2021	Dec 2020
Income Statement
Total Revenue	162.83M	154.95M	130.65M	152.61M	184.71M	188.86M
Gross Profit	74.73M	71.95M	57.49M	65.04M	97.44M	105.61M
EBITDA	18.74M	20.40M	24.55M	40.49M	79.63M	88.57M
Net Income	2.40M	4.00M	4.83M	24.94M	60.54M	73.48M
Balance Sheet
Total Assets	259.11M	257.17M	316.33M	330.42M	209.22M	172.30M
Cash, Cash Equivalents and Short-Term Investments	26.86M	23.07M	89.03M	85.94M	102.39M	65.56M
Total Debt	20.36M	34.05M	100.66M	113.60M	15.68M	29.70M
Total Liabilities	78.26M	78.31M	141.16M	157.75M	49.00M	64.45M
Stockholders Equity	180.85M	178.85M	175.17M	172.34M	159.91M	107.11M
Cash Flow
Free Cash Flow	7.46M	13.45M	22.71M	39.01M	63.61M	52.02M
Operating Cash Flow	8.99M	16.70M	26.77M	41.85M	65.46M	54.31M
Investing Cash Flow	-9.30M	-10.74M	-318.00K	-141.76M	-5.47M	-3.98M
Financing Cash Flow	-63.34M	-72.09M	-23.50M	82.31M	-23.75M	7.67M

Eurobio-Scientific SA Technical Analysis

• Technical Analysis Sentiment: Negative
• Last Price: 24.15
• 50DMA: Negative
• 100DMA: Negative
• 200DMA: Negative
• MACD: Positive
• RSI: Neutral
• STOCH: Neutral

Evaluating momentum and price trends is crucial in stock analysis to make informed investment decisions. For FR:ALERS, the sentiment is Negative. The current price of 24.15 is above the 20-day moving average (MA) of 23.20, above the 50-day MA of 23.63, and below the 200-day MA of 24.62, indicating a bearish trend. The MACD of -0.24 indicates Positive momentum. The RSI at 43.00 is Neutral, neither overbought nor oversold. The STOCH value of 37.61 is Neutral, not indicating any strong overbought or oversold conditions. Overall, these indicators collectively point to a Negative sentiment for FR:ALERS.

Eurobio-Scientific SA Peers Comparison

Name	Overall Rating	Market Cap	P/E Ratio	ROE	Dividend Yield	Revenue Growth	EPS Growth
ALERS	55 Neutral	€225.12M	26.96	1.32%	―	12.47%	-65.87%
Sector *	51 Neutral	$7.86B	-0.30	-43.30%	2.27%	22.53%	-2.21%
ALIKO	50 Neutral	€23.21M	-5.20	-17.18%	―	138.92%	11.14%
ALMDT	47 Neutral	€180.97M	-0.80	59.08%	―	6.75%	15.48%
ALNOV	44 Neutral	€28.13M	-2.19	-14.58%	―	5.10%	17.34%
EAPI	44 Neutral	€119.90M	-1.02	―	―	-9.32%	56.88%